Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia

NCT02705547 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT02705547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02705547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
August 4, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich ataxia